contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vimian-group-acquires-veterinary-orthopedic-implants-business-in-the-us

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vimian Group is a group operating in animal health. The company, through its subsidiaries, delivers pharmaceuticals and technical solutions to veterinarians, laboratories and pet owners. The products include, for example, pharmaceuticals with associated clinical research and digital platforms for veterinary clinics. The company operates on a global level with headquarters in Stockholm.

Vimian Group

Vimian Group has acquired the assets of New Generation Devices (NGD), a veterinary orthopedic implants company in New Jersey, US. The acquired business has annual revenues of around USD 4.5 ...

<div class="mfn-preamble"><p><strong>Vimian Group has acquired the assets of New Generation Devices (NGD), a veterinary orthopedic implants company in New Jersey, US. The acquired business has annual revenues of around USD 4.5 million.</strong></p></div><div class="mfn-body"><p>Vimian’s MedTech segment Movora has acquired the assets of New Generation Devices (NGD). Founded in 2001, NGD offers a selected range of veterinary orthopedic implants to veterinary clinics across the United States with focus on implants for ruptured cruciate ligaments (TPLO) and fracture plates. As part of the transaction, Movora has also acquired an exclusive license in the veterinary field that gives access to Citrate-BP, a synthetic biomaterial to guide tissue regeneration.</p><p><em>“Through this acquisition we gain access to a new loyal customer base to which we can offer our full product portfolio of veterinary orthopedic implants and surgical instrumentation. We also gain the global license to a new, innovative technology in the veterinary market. This acquisition has a clear strategic fit with Movora and significant synergy potential, says Chris Sidebotham</em>, Co-CEO of Vimian’s MedTech segment Movora.</p><p>The acquisition will have a marginal impact on Vimian Group's earnings per share in the current financial year. The acquisition was consolidated into Vimian Group’s MedTech segment on 1 August.</p></div><div class="mfn-footer mfn-contacts mfn-ddfb1f46825b"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p><strong>Maria Dahllöf Tullberg</strong><br>Head of IR, Communications &amp; Sustainability<br><a rel="nofollow noopener" href="mailto:maria.tullberg@vimian.com">maria.tullberg@vimian.com</a><br>+46 736 26 88 86</p></div><div class="mfn-footer mfn-about mfn-b6e2606a1fc5"><p><strong class="mfn-heading-1">About Vimian</strong></p><hr><p>Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 700 people and have a combined annual turnover of approximately EUR 170 million. FNCA Sweden AB is appointed the Company’s Certified Adviser,&nbsp;<a rel="nofollow noopener" href="mailto:info@fnca.se">info@fnca.se</a>,&nbsp;+46 (0) 8-528 00&nbsp;399. For more information, please visit: <a rel="nofollow noopener" href="http://www.vimian.com.">www.vimian.com.</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/c2e05fa4-7fb9-4e1c-a0f5-1360c5f34807/vimian-group-acquires-veterinary-orthopedic-implants-business-in-the-us.pdf" class="mfn-generated mfn-primary">Vimian Group acquires veterinary orthopedic implants business in the US</a></p></div>